Overview

Air Versus Oxygen for Intermediate-Risk Pulmonary Embolism (AIRE)

Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of the treatment with supplementary oxygen added to conventional anticoagulant treatment in patients with Intermediate-risk pulmonary embolism. The secondary objective is to evaluate the safety of the treatment with supplementary oxygen added to conventional anticoagulant treatment in patients with Intermediate-risk pulmonary embolism.
Phase:
Phase 3
Details
Lead Sponsor:
Ministry of Health, Spain
Collaborator:
Sociedad Española de Neumología y Cirugía Torácica
Treatments:
Anticoagulants